

Supplementary Online Content

Cercek A, Roxburgh CS, Strombom P, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer [published online March 22, 2018]. *JAMA Oncol*. doi:10.1001/jamaoncol.2018.0071

eTable 1. FOLFOX chemotherapy doses received

eTable 2. Binary logistic regression analysis of CR at 12 months (pCR or cCR) in relation to patient and tumor characteristics (N=628)

eFigure. Trends in the delivery of neoadjuvant therapy for LARC at MSK

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. FOLFOX Chemotherapy Doses Received^a

Characteristic	ChemoRT with Planned Adjuvant Chemotherapy (n=101 ^b)	TNT (n=249 ^b)	P
5-FU			
Average % of planned dose received	88.4	95.9	.003
% of patients requiring dose reduction	50.5	25.7	< .001
% of patients requiring dose reduction but receiving full no. of cycles	34.2	22.1	.035
No. (%) of patients receiving:			
> 75% of planned dose	80 (79.2)	231 (92.8)	< .001
> 90% of planned dose	56 (55.4)	209 (83.9)	< .001
No. (%) of patients receiving:			
> 6 cycles	84 (83.2)	236 (94.8)	< .001
8 cycles	76 (75.2)	235 (94.4)	< .001
Oxaliplatin			
Average % of planned dose received	73.3	90.4	< .001
% of patients requiring dose reduction	76.2	53.8	< .001
% of patients requiring dose reduction but receiving full no. of cycles	42.9	41.0	.827
No. (%) of patients receiving:			
> 75% of planned dose	60 (59.4)	210 (84.3)	< .001
> 90% of planned dose	28 (27.7)	152 (61.0)	< .001
No. (%) of patients receiving:			
> 6 cycles	64 (63.4)	214 (85.9)	< .001
8 cycles	42 (41.6)	195 (78.3)	< .001


^aCAPOX regimens were excluded from analysis.

^bNumber of patients with data available from the electronic medical record

eTable 2. Binary Logistic Regression Analysis of CR at 12 Months (pCR or cCR) in Relation to Patient and Tumor Characteristics (N=628)

Characteristic		Univariate Analysis	
		OR (95% CI)	p
Age	< 65 yr		
	65-75 yr	0.98 (0.63-1.36)	.703
	> 75 yr	3.28 (1.81-5.95)	<.001
Sex	Female		
	Male)	1.33 (0.93-1.90)	.117
Year of diagnosis	2009-11		
	2012-13	1.84 (1.20-2.83)	.005
	2014-15	1.72 (1.10-2.67)	.017
Tumor height	≤6 cm		
	7-15 cm	0.90 (0.63-1.29)	.578
Weeks to surgery ^a	< 8 weeks		
	8-12 weeks	1.02 (0.63-1.67)	.925
	> 12 weeks	0.76 (0.38-1.54)	.456
Clinical T stage	cT4		
	cT3	1.86 (0.89-3.91)	.101
	cT1-2	4.07 (1.61-10.33)	.003
Clinical N stage	cN0		
	cN+	0.76 (0.50-1.16)	.203
Treatment	CRT with planned adjuvant CT TNT	2.06 (1.44-2.96)	< .001

^aPatients who underwent surgery within 12 months.



eFigure 1. Trends in the delivery of neoadjuvant therapy for LARC (chemoRT with planned adjuvant chemotherapy and TNT) at MSK. The data are percentages of all treated cases per year of diagnosis.